(AMPH) Amphastar P - Ratings and Ratios
Injectable, Inhalation, Intranasal, Generic, Biosimilar
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 41.8% |
| Value at Risk 5%th | 63.9% |
| Relative Tail Risk | -7.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.21 |
| Alpha | -54.42 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.633 |
| Beta | 0.688 |
| Beta Downside | 0.575 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.28% |
| Mean DD | 30.69% |
| Median DD | 30.25% |
Description: AMPH Amphastar P November 16, 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a U.S.–based biopharma that focuses on developing, manufacturing, and commercializing injectable, inhalation, and intranasal products across the United States, China, and France. Its marketed portfolio includes the nasal spray BAQSIMI for severe hypoglycemia, the OTC epinephrine inhaler Primatene Mist for intermittent asthma, and a suite of emergency-use injectables such as Enoxaparin, REXTOVY, Naloxone, Glucagon, and Cortrosyn. The company also supplies a range of specialty injectables (e.g., Amphadase hyaluronidase, lidocaine formulations, vitamin K1, morphine, lorazepam, neostigmine, isoproterenol, ganirelix, vasopressin, regadenoson, and albuterol) and distributes insulin APIs. In addition, Amphastar is advancing generic injectable, inhalation, and biosimilar candidates, including an intranasal epinephrine product for allergic reactions.
According to Amphastar’s FY 2023 Form 10-K, the company generated $184 million in total revenue-a 12 % increase YoY driven primarily by higher sales of its opioid-overdose and hypoglycemia products. Cash and cash equivalents stood at $115 million, providing roughly 1.5 years of runway at current burn rates, while the net loss widened to $31 million as R&D spending rose 18 % to fund its biosimilar pipeline. The firm’s gross margin on injectable generics averaged 38 %, reflecting the premium pricing power of sterile-product manufacturing.
Key macro drivers for Amphastar’s market include (1) the aging U.S. population and rising prevalence of chronic conditions that increase demand for sterile injectables; (2) sustained public-health focus on opioid-overdose treatment, which underpins recurring demand for Naloxone and REXTOVY; and (3) regulatory incentives for generic sterile drug approvals, which can accelerate time-to-market but also heighten competitive risk from larger contract manufacturers.
For a deeper quantitative assessment of AMPH’s valuation relative to peers, the ValueRay platform offers a granular breakdown of cash-flow forecasts and risk-adjusted returns.
AMPH Stock Overview
| Market Cap in USD | 1,212m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-06-25 |
| Return 12m vs S&P 500 | -48.8% |
| Analyst Rating | 3.67 of 5 |
AMPH Dividends
Currently no dividends paidAMPH Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -4.05% |
| CAGR/Max DD Calmar Ratio | -0.06 |
| CAGR/Mean DD Pain Ratio | -0.13 |
| Current Volume | 524.4k |
| Average Volume | 417.7k |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (111.6m TTM) > 0 and > 6% of Revenue (6% = 43.4m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -4.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 60.04% (prev 53.66%; Δ 6.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 152.3m > Net Income 111.6m (YES >=105%, WARN >=100%) |
| Net Debt (440.3m) to EBITDA (221.2m) ratio: 1.99 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.7m) change vs 12m ago -8.07% (target <= -2.0% for YES) |
| Gross Margin 49.36% (prev 52.41%; Δ -3.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.05% (prev 46.67%; Δ -1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.37 (EBITDA TTM 221.2m / Interest Expense TTM 25.3m) >= 6 (WARN >= 3) |
Altman Z'' 4.39
| (A) 0.26 = (Total Current Assets 639.5m - Total Current Liabilities 205.2m) / Total Assets 1.67b |
| (B) 0.39 = Retained Earnings (Balance) 642.5m / Total Assets 1.67b |
| (C) 0.10 = EBIT TTM 160.9m / Avg Total Assets 1.61b |
| (D) 0.72 = Book Value of Equity 637.2m / Total Liabilities 889.5m |
| Total Rating: 4.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.63
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 7.12% = 3.56 |
| 3. FCF Margin 15.66% = 3.91 |
| 4. Debt/Equity 0.85 = 2.16 |
| 5. Debt/Ebitda 1.99 = 0.02 |
| 6. ROIC - WACC (= 3.72)% = 4.66 |
| 7. RoE 14.80% = 1.23 |
| 8. Rev. Trend 76.69% = 5.75 |
| 9. EPS Trend 36.70% = 1.84 |
What is the price of AMPH shares?
Over the past week, the price has changed by -8.84%, over one month by +6.91%, over three months by -16.35% and over the past year by -41.84%.
Is AMPH a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AMPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.3 | 27.4% |
| Analysts Target Price | 32.3 | 27.4% |
| ValueRay Target Price | 21.6 | -14.7% |
AMPH Fundamental Data Overview November 15, 2025
P/E Trailing = 11.6681
P/S = 1.6753
P/B = 1.647
P/EG = 2.77
Beta = 0.917
Revenue TTM = 723.3m USD
EBIT TTM = 160.9m USD
EBITDA TTM = 221.2m USD
Long Term Debt = 608.6m USD (from longTermDebt, last quarter)
Short Term Debt = 8.75m USD (from shortTermDebt, last quarter)
Debt = 656.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 440.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.59b USD (1.21b + Debt 656.8m - CCE 278.6m)
Interest Coverage Ratio = 6.37 (Ebit TTM 160.9m / Interest Expense TTM 25.3m)
FCF Yield = 7.12% (FCF TTM 113.3m / Enterprise Value 1.59b)
FCF Margin = 15.66% (FCF TTM 113.3m / Revenue TTM 723.3m)
Net Margin = 15.43% (Net Income TTM 111.6m / Revenue TTM 723.3m)
Gross Margin = 49.36% ((Revenue TTM 723.3m - Cost of Revenue TTM 366.3m) / Revenue TTM)
Gross Margin QoQ = 51.42% (prev 49.59%)
Tobins Q-Ratio = 0.95 (Enterprise Value 1.59b / Total Assets 1.67b)
Interest Expense / Debt = 0.96% (Interest Expense 6.28m / Debt 656.8m)
Taxrate = 19.35% (4.16m / 21.5m)
NOPAT = 129.8m (EBIT 160.9m * (1 - 19.35%))
Current Ratio = 3.12 (Total Current Assets 639.5m / Total Current Liabilities 205.2m)
Debt / Equity = 0.85 (Debt 656.8m / totalStockholderEquity, last quarter 776.7m)
Debt / EBITDA = 1.99 (Net Debt 440.3m / EBITDA 221.2m)
Debt / FCF = 3.89 (Net Debt 440.3m / FCF TTM 113.3m)
Total Stockholder Equity = 754.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.70% (Net Income 111.6m / Total Assets 1.67b)
RoE = 14.80% (Net Income TTM 111.6m / Total Stockholder Equity 754.5m)
RoCE = 11.81% (EBIT 160.9m / Capital Employed (Equity 754.5m + L.T.Debt 608.6m))
RoIC = 9.54% (NOPAT 129.8m / Invested Capital 1.36b)
WACC = 5.82% (E(1.21b)/V(1.87b) * Re(8.55%) + D(656.8m)/V(1.87b) * Rd(0.96%) * (1-Tc(0.19)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.17%
[DCF Debug] Terminal Value 79.27% ; FCFE base≈136.0m ; Y1≈161.7m ; Y5≈253.3m
Fair Price DCF = 85.63 (DCF Value 3.93b / Shares Outstanding 46.0m; 5y FCF grow 20.13% → 3.0% )
EPS Correlation: 36.70 | EPS CAGR: 9.20% | SUE: 0.47 | # QB: 0
Revenue Correlation: 76.69 | Revenue CAGR: 13.62% | SUE: 1.22 | # QB: 1
Additional Sources for AMPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle